Video

Dr. Zhang on adaptive phase 3 trial of nivolumab, ipilimumab, and cabozantinib in kidney cancer

Author(s):

Urology Times staff

Tian Zhang, MD, discusses the ongoing phase 3 PDIGREE study (NCT03793166) exploring immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) followed by nivolumab or nivolumab with cabozantinib (Cabometyx) for patients with intermediate/poor-risk metastatic clear cell renal cell carcinoma

Zhang, who is an associate professor at UT Southwestern Medical Center, was interviewed during the 2021 Kidney cancer research summit in Philadelphia, Pennsylvania.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Related Content
Behavioral intervention may improve psychological distress after testicular cancer
November 25th 2024

Behavioral intervention may improve psychological distress after testicular cancer

Hannah Clarke
The study showed significant reductions in both anxiety and depressive symptoms following the intervention.
Destigmatizing Urology: Dr. Pettaway discusses penile cancer
March 29th 2022

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Urology Times staff
“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
March 31st 2021

Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists

Urology Times staff
“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
October 29th 2024

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

Hannah Clarke Gina Mauro
The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
September 25th 2024

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

Hannah Clarke
"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.
© 2024 MJH Life Sciences

All rights reserved.